Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders

Current Pharmaceutical Design

Volumn 16, Issue 25, 2010, Pages 2799-2817

  Naoi, Makoto ^a   Maruyama, Wakako ^b  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Alzheimer's disease; Mao inhibitors; Mitochondria; Monoamine oxidase; Neuroprotection; Neurotrophic factors; Parkinson's disease; Programmed cell death

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ADENOSINE TRIPHOSPHATE; ANTIDEPRESSANT AGENT; BROFAROMINE; CALPASTATIN; CEP 1347; CLORGYLINE; CYCLOSPORIN; FR 255595; GLYCOSYLTRANSFERASE INHIBITOR; IPRONIAZID; ISONIAZID; K 252A; LADOSTIGIL; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N (2 PROPYNYL) 1 INDANAMINE; NEUROTRANSMITTER; PHENELZINE; RASAGILINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; ROTTLERIN; SELEGILINE; TOLOXATONE; TRANYLCYPROMINE; TRANYLCYPROMINE DERIVATIVE; TV 1012; UNCLASSIFIED DRUG; UNINDEXED DRUG; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;

ADJUVANT THERAPY; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BRAIN MITOCHONDRION; CELL DEATH; CLINICAL TRIAL; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; HUMAN; HYPERTENSIVE CRISIS; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

EID: 77957968479     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793176527     Document Type: Article

References (267)

1. Martin JB. Molecular basis of the neurodegenerative disorders. NEng J Med 1999; 340: 1970-1980.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy Physiol Rev 2001; 81: 741-766.
3. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson'sdisease. N Eng J Med 2003; 348: 1356-1364.
4. Sabbagh MN, Shah F, Reid RT, et al. Pathologic and nicotinicreceptor binding differences between mild cognitive impairment,Alzheimer disease, and normal aging. Arch Neurol 2006; 63: 1771-1776.
5. Dauer W, Przedborski S. Parkinson's disease: mechanisms andmodels. Neuron 2003; 39: 889-909.
6. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenera-tive disease. J Clin Invest 2005; 115: 1449-1457.
7. Terzioglu M, Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 2008; 275: 1384-1391.
8. Heintz N, Zoghbi H. α-Synuclein -a link between Parkinson andAlzheimer disease? Nat Genet 1997; 17: 325-327.
9. Lippa CF, Fujiwara H, Mann DMA, et al. Lewy bodies containaltered -synuclein in brains of many familial Alzheimer's diseasepatients with mutations in presenilin and amyloid precursor proteingenes. Am J Pathol 1998; 153: 1365-1370.
10. Mandel PK, Pettegrew JW, Masliah E, Hamilton RL, Mandel R.Interaction between abeta peptide and alpha synuclein: molecularmechanisms in overlapping pathology of Alzheimer's and Parkin-son's in dementia with Lewy body disease. Neurochem Res 2006;31: 153-162.
11. McGeer PL, McGeer EG. The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. ExpNeurol 2008; 212: 235-238.
12. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008; 116: 1-16.
13. Braak H, Tredici KD, Rüb U, de Vos RAI, Steuer ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson's disease.Neurobiol Aging 2003; 24: 197-211.
14. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss isgreater in the locus coeruleus than nucleus basalis and substantianigra in Alzheimer and Parkinson diseases. Arch Neurol 2003; 60:337-341.
15. Shannak K, Rajput A, Rozdilsky B, Kish G, Gilbert K, Horykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 1994; 639: 33-41.
16. Gsell W, Jungkunz G, Riederer P. Functional neurochemistry ofAlzheimer's disease. Curr Pharm Des 2004; 10: 265-293.
17. Liu Y, Yoo MY, Savonenko A, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in atransgenic mouse model of Alzheimer's disease. J Neurosci 2008;28: 13805-13814.
18. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes tobehavior. Ann Rev Neurosci 1999; 22: 197-217.
19. Edmondson DE, Mattevi A, Binda C, Li M, Hubalek F. Structureand mechanism of monoamine oxidase. Curr Med Chem 2004; 11:1983-1993.
20. Youdim MBH, Bakhle YS. Monoamine oxidase isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006; 147: 287-296.
21. Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka T. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm 2006; (Suppl 71): 67-77.
22. Edmondson DE, Binda C, Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B.Arch Biochem Biophys 2007; 464: 269-276.
23. Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1986; 45: 111-118.
24. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenylto Madopar treatment in Parkinson's disease; a long-term study. JNeural Transm 1985; 64: 113-127.
25. Riederer P, Lachenmayer L. Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004; 11: 2033-2043.
26. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7:295-309.
27. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxiciy of 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine inhibitors. Nature 1984;311: 467-469.
28. Parkinson Study Group. Effects of tocopherol and deprenyl on progression of disability in early Parkinson's disease. N Engl JMed 1993; 328: 176-183.
29. Yu PH, Davis BA, Boulton AA. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradre-naline depletion in the mouse hippocampus. J Neurochem 1994;63: 1820-1828.
30. Maruyama W, Takahashi T, Naoi M. Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 1998; 70:2510-2515.
31. Thomas T. Monoamine oxidase-B inhibitors in the treatment ofAlzheimer's disease. Neurobiol Aging 2000; 21: 343-348.
32. Riederer P, Danielczyk W, Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neuro Toxicol 2004; 25: 271-277.
33. Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamine in Parkinson's disease: intracellular mechanism underlying antiapoptotic function and search for clinical markers. J Neural Transm 2007; (Suppl 72):121-131.
34. Naoi M, Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Expert Rev Neurother 2009; 9: 1233-1250.
35. Youdim MBH, Buccafusco JJ. CNS Targets for multi-functionaldrugs in the treatment of Alzheimer's and Parkinson's disease. J Neural Transm 2005; 112: 519-537.
36. Avramovich-Tirosh Y, Reznichienko L, Mit T, et al. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants,M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 2007;4: 403-411.
37. Houghton PJ, Howes MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 2005; 14: 6-22.
38. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989; 163: 1450-1455.
39. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease.Lancet 1989; 1: 1269.
40. Bindoff LA, Birch-Machin M, Cartlidge EF, Parker WD Jr, Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet 1989; 2: 49.
41. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26: 719-723.
42. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochon-drial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm [P-D Sect] 1992; 4: 27-34.
43. Bender A, Krishnan KJ, Morris CM, et alet al. High levels of mito-chondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat Genet 2006; 38: 515-517.
44. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. NatGenet 2006; 38: 518-520.
45. Keeney PM, Xie J, Capaldi RA, Benett JB Jr. Parkinson's diseasebrain mitochondrial complex I has oxidatively damaged subunits and its functionally impaired and misassembled. J Neurosci 2006;26: 5256-5264.
46. Henchcliffe C, Beal MF. Mitochondrial biology and oxidativestress in parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600-609.
47. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease. J Neurochem 2008; 107: 317-328.
48. Naoi M, Maruyama W, Yi H, et al. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathiony-lation in mitochondria: involvement of the protein and melanin component. J Neurochem 2008; 105: 2489-2500.
49. Schapira AHV. Mitochondrial dysfunction in Parkinson's disease.Cell Death Differ 2007; 14: 1261-1266.
50. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Ananda-theerthavarada HK. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cul-tures and Parkinson disease brain. J Biol Chem 2008; 283: 9089-9100.
51. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 2006; 26:9057-9068.
52. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial functionin neuronal cells. J Cell Biol 2003; 161: 41-51.
53. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, ReddyPH. Mitochondria are a direct site of A accumulation in Alzheimer's disease neurons: implications for free radical generationand oxidative damage in disease progression. Human Mol Gene 2006; 15: 1437-1449.
54. Petersen CAH, Alikhani N, Behbahni H, et al. The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 2008; 105: 13145-13150.
55. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90: 7951-7955.
56. Wang X, Su B, Lee H, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29:9090-9103.
57. Brüeler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009; 218: 235-246.
58. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
59. Behl C. Apoptosis and Alzheimer's disease. J Neural Transm 2000;107: 1325-1344.
60. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosisin parkinson's disease: signals for neuronal degradation. Ann Neu-rol 2003; 53 (suppl 3): S61-S72.
61. Rohn TT, Head E. Caspase activation in Alzheimer's disease: Earlyto rise and late to bed. Rev Neurosci 2008; 19: 383-393.
62. Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer'sdisease. J Pharmacol Sci 2005; 97: 312-316.
63. Guo H, Albrecht A, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active caspase-6 and caspase-6-cleaved tau in neurophil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol 2004; 165: 523-531.
64. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neuronsin Parkinson's disease. Proc Natl Acad Sci USA 2000; 97: 2875-2880.
65. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF- kb is increased in dopaminergic neurons of patients with Parkinson'sdisease. Proc Natl Acad Sci USA 1997; 94: 7531-7536.
66. Kitamura Y, Shimohara S, Ota T, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res 1998; 780: 260-269.
67. Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy- a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171: 87-98.
68. Narendra D, Tanaka A, Suen D-F, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy.J Clin Biol 2008; 183: 795-803.
69. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2:Release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.
70. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-parkinson drug,rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin,N-methyl(R)salsolinol. J Neurochem 2001; 78:727-735.
71. Soane L, Fiskum G. Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins. J Bioeng Biomembr 2005; 37: 179-190.
72. Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins.Cell Death Differ 2006; 13: 1250-1255.
73. Song YS, Park HJ, Kim SY, et al. Protective role of Bcl-2 on β-amyloid-induced cell death of differentiated PC12 cells: reductionof NF- KB and p38 MAP kinase activation. Neurosci Res 2004; 49:69-80.
74. Zhu X, Wang Y, Ogawa O, et al. Neuroprotective properties of Bcl-w in Alzheimer disease. J Neurochem 2004; 89: 1233-1240.
75. Bozyczko-Coyne D, O'Kane TM, Wu ZL, et al. CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ-induced cortical neuron apoptosis. J Neurochem 2001; 77:849-863.
76. Sugioka R, Shimizu S, Funatsu T, et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 2002; 22:8432-8440.
77. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol,an endogenous neurotoxin, and its inhibited by Bcl-2 and rasa-giline, N-propargyl-1(R)-aminoindan. J Neurochem 2002; 82: 913-923.
78. Roux PP, Dorval G, Boudreau M, et al. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK. J Biol Chem 2002; 277: 49473-49480.
79. Crocker SJ, Smith PD, Jackson-Lewis V, et al. Inhibition of cal-pains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 2003; 23: 4081-4091.
80. Yang L, Sugama S, Mischak RP, et al. A novel systematicallyactive caspase inhibitor attenuates the toxicities of MPTP,malonate, and 3NP in vivo. Neurobiol Dis 2004; 17: 250-259.
81. Iwashita A, Yamazaki S, Mihara K, et al. Neuroprotective effectsof a novel poly(ADP-Ribose) polymerase-1 inhibitor, 2-{3- [4-(4-chlorophenyl)- 1-piperazinyl]propyl}-4(3H)-quinazolinone(FR255595), in an in vitro model of cell death and in mouse 1-methyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exper Ther 2004; 309: 1067-1078.
82. Pan J, Wang G, Yang HQ, et al. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine trough inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways. Mol Pharmacol 2007; 72: 1607-1618.
83. Zhang D, Anantharam V, Kanthasamy A, Kanthasamy AG. Neuro-protective effect of protein kinase C inhibitor rottlerin in cell cul-ture and animal models of Parkinson's disease. J Pharmacol Exp Ther 2007; 322: 913-922.
84. Karunakaran S, Saeed U, Mishra M, et al. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated mice. J Neuro sci 2008;28: 1250-1259.
85. Rohn TT, Head E. Caspases as the rapeutic targets in Alzheimer'sdisease: Is it time to "cut" to the chase? Int J Clin Exp Pathol 2009;2: 108-118.
86. Johnston JP. Some observations upon a new inhibitors of mono-amine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285-1297.
87. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972; 5: 393-408.
88. Shih JC. Cloning, after cloning, knock-out mice, and physiologicalfunctions of MAO A and B. Neuro Toxicol 2004; 25: 21-30.
89. Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, HeinsenH, Beckmann H. Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 1989: 499: 81-86.
90. Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases inbrain monoamine oxidase B in living healthy human subjects. Neu-robiol Aging 1997; 18: 431-435.
91. Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol 2004; 30: 77-89.
92. Danielczyk W, Steifler M, Konradi C, Riederer P, Moll G. PlateletMAO-B activity and the psycopathology of Parkinson's disease,senile dementia and multi-infarct dementia. Acta Psychiatr Scand 1988; 78: 730-736.
93. Grünblatt E, Schösser R, Fischer P, et al. Oxidative stress relatedmarkers in the "VITA" and the centenarian projects. Neurobiol Ageing 2005; 26: 429-438.
94. Langston JW, Irwin I, Langston EB, Forna LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984; 225:1480-1482.
95. Costa P, Checkoway H, Levy D, et al. Association of a polymor-phism in intron 13 of the monoamine oxidase B gene with Parkinson disease. Am J Med Genet 1997; 74: 154-216.
96. Nakamoto M, Tun Z, Shimada S, Honda K. Detection and analysisof four polymorphic markers at the human monoamine oxidase(MAO) gene in Japanese controls and patients with Parkinson'sdisease. Biochem Biophys Res Commun 1998; 247: 452-456.
97. Kang SJ, Scott WK, Li YJ, et al. Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson's disease. Mov Disord 2006; 21: 2175-2180.
98. Gao X, Scott WK, Wang G, et al. Gene-gene interaction between EGF20 and MAOB in Parkinson's disease. Ann Hum Genet 2008;72 (Pt 2): 157-162.
99. Gottfries CG, Adoldsson R, Aquilonius SM, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).Neurobiol Aging 1983; 4: 261-271.
100. Emilsson L, Saertre P, Balciuniene J, Castensson A, Cairns N, Jazin EE. Increased monoamine oxidase messenger RNA expres-sion levels in frontal cortex of Alzheimer's disease patients. Neu-rosci Lett 2002; 326: 56-60.
101. Takehashi M, Tanaka S, Masliah E, Ueda K. Association of mono-amine oxidase A gene polymorphism with Alzheimer's disease andLewy body variant. Neurosci Lett 2002; 327: 79-82.
102. Wu YH, Fischer DF, Swaab DF. A promotor polymorphism in the monoamine oxidase gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res 2007; 1167: 13-19.
103. Wu YH, Feenstra MGP, Zhou JN, et al. Molecular changes under-lying pineal melatonin levels in Alzheimer disease: alterations inpreclinical and clinical stages. J Clin Endocrinol Metab 2003; 88:5898-5906.
104. Maruyama W, Abe T, Tohgi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in parkinsonian cerebrospinal fluid. Ann Neurol 1996; 40: 119-122.
105. Maruyama W, Naoi M, Kasamatsu T, et al. An endogenous dopa-minergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA dam-age in human dopaminergic neuroblastoma SH-SY5Y cells. J Neu-rochem 1997; 69: 322-329.
106. Naoi M, Maruyama W, Dostert P, et al. Dopamine-derived en-dogenous 1(R),2(N)-dimethyl-6,7- dihydroxy-1,2,3,4-tetrahydroiso-quinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat:biochemical, pathological and behavioral studies. Brain Res 1996;709: 285-295.
107. Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergicneurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 2006; 96: 541-549.
108. Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M.Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm 2009; 116: 1371-1381.
109. Ou X-M, Chen Km, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 2006; 103: 10923-10928.
110. Kline NS. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol 1958; 19 (2, suppl 1): 72-78.
111. Verga E, Tringer L. Clinical trial of a new type promptly psychoergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250"). Acta Med Acad Sci Hung 1967; 23: 289-295.
112. Robinson DS. Monoamine oxidase inhibitors: a new generation.Gen Psychopharmacol 2002; 36: 124-138.
113. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversi-ble inhibitors of monoamine oxidase type A moclobemide and bro-faromine for the treatment of depression. Neuropsychopharmacol 1999; 20: 226-247.
114. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression - a retrospective study. J Affect Disord 2005; 89: 183-188.
115. Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effects after L-dopa treatment by inhibitorof MAO-B, deprenyl. J Neural Transm 1975; 36: 303-326.
116. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implicationsof combined treatment with Madopar and l-deprenyl in Parkinson'sdisease. A long-term study. Lancet 1977; 1(8009): 439-443.
117. Magyar K, Szende B. Deprenyl, a selective MAO-B inhibitor,with apoptotic and anti-apoptotic properties. Neuro Toxicol 2004;25: 233-242.
118. Ebadi M, Brown-Borg H, Ren A, et al. Therapeutic efficiency ofselegiline in neurodegenerative disorders and neurological diseases.Curr Drug Targets 2006; 7: 1513-1529.
119. Thomas CE, Huber EW, Ohlweiler DF. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyland MDL 72,974A: implications for protection of biological sub-strates. Free Radic Biol Med 1997; 22: 733-737.
120. Carrillo MC, Kanai S, Nokubo M, Kitani K. Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci1 1991; 48: 517-521.
121. Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redoxprotein thioredoxin in cytoprotective mechanism evoked by deprenyl. Mol Pharmacol 2005; 68: 1408-1414.
122. Elsworth JD, Sandler M, Lees AJ, Ward C, Stern GM. The contri-bution of amphetamine metabolites of deprenyl to its antipark-insonian properties. J Neural Transm 1982: 54: 105-110.
123. Yasar S, Justinova Z, Lee SH, et al. Metabolic transformation playsa primary role in the psychostimulant-like discriminative-stimuluseffects of selegiline [(R)-deprenyl]. J Pharmacol Exp Ther 2006; 317: 387-394.
124. Knoll J. The striatal dopamine dependency of life span in male rats:longevity study with deprenyl. Mech Age Dev 1988; 46: 237-262.
125. Kitani K, Kanai S, Sato Y, Ohta M, Ivy GO, Carrillo MC. Chronic treatment of deprenyl prolongs the life span in male Fischer 344 rats: Further evidence. Life Sci 1993; 52: 281-288.
126. Magyar K, Szende B, Lemgyel J, Tekes K. The pharmacology of B-type selective monoamine oxidase inhibitors: milestones in deprenyl research. J Neural Transm 1996; (Suppl 48): 29-43.
127. Finberg JPM, Tenne M, Youdim MBH. Tyramine antagonistic properties of AGN 1135 - an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981; 73: 65-64.
128. Finberg JPM, Lamensdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neu-ral Transm 1996; Suppl 48: 95-101.
129. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochon-drial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506.
130. Götz ME, Breithaupt W, Sautter J, et al. Chronic TVP-1012(rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm 1998;Suppl 52: 271-278.
131. Yu PH, Davis BA. Inversion of selectivity of N-substituted propar-gylamine oxidase inhibitors following structural modifications toquaternary salts. Int J Biochem Cell Biol 1999; 31: 1391-1397.
132. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin,N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 2006; 113: 21-32.
133. Yu PH, Davis BA, Durden DA, Terleckyj I, Nicklas WG, Boulton AA. Neurochemical and neuroprotective effects of some aliphatic propargylamines: New selective nonamphetamine-like monoamine oxidase B inhibitors. J Neuro chem 1994; 62: 697-704.
134. Heikkila RE, Duvoisin RC, Finberg JPM, Youdim MBH. Preven-tion of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharma-col 1985; 16: 313-317.
135. Spooren WPJM, Walsmeier P, Gentsch C. The effect of a sub-chronic post-lesion treatment with deprenyl on the sensitivity of6-OHDA-lesioned rats to apomorphine and d-amphetamine J Neu-ral Transm 1999; 106: 825-833.
136. Kupsch A, Sautter J, Götz ME et al. Monoamine oxidase-inhibitionand MPTP-induced neurotoxicity in the non-human primate: com-parison of rasagiline (TVP1012) with selegiline. J Neural Transm 2001; 108: 985-1009.
137. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW. Pro-tection against DSP-4-induced neurotoxicity by deprenyl is not re-layed to its inhibition of MAO B. Eur J Pharmacol 1990; 184: 119-126.
138. Yu PH, Davis BA, Fang J, Boulton AA. Neuroprotective effects ofsome monoamine oxidase-B inhibitors against DSP-4-inducednoradrenaline depletion in the mouse hippocampus. J Neurochem 1994; 63: 1820-1828.
139. Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E. Deficitsin cholinergic neurotransmission markers induced by ethylcholinemustard aziridinium (AF64A) in the rat hippocampus: sensitivity totreatment with the monoamine oxidase-B inhibitor L-deprenyl.Drugs Exp Clin Res 1992; 18: 163-171.
140. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing byrasagiline (TVP-1012) of cholinergic functions and behavior in thepostnatal anoxia rat. Pharmacol Biochem Behav 1998; 60: 378-393.
141. Gelowitz DL, Paterson IA. Neuronal sparing and behavioral effectsof the antiapoptotic dug, (-)deprenyl, following kainic acid admini-stration. Pharmacol Biochem Behav 1999; 62: 255-262.
142. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotectiveeffect of rasagiline, a selective monoamine oxidase-B inhibitor,against closed head injury in the mouse. Eur J Pharmacol 1999;366: 127-135.
143. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008; 210: 421-427.
144. Tatton WG, Ju WYL, Holland D, Tai C, Kwan M. Deprenylreduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994; 63: 1572-1575.
145. Semkova I, Wolz P, Schilling M, Krieglein J. Selegiline enhancesNGF synthesis and protects central nervous system neurons fromexcitotoxic and ischemic damage. Eur J Pharmacol 1996; 315: 19-30.
146. Finberg JPM, Takeshima T, Johnston JM, Commissiong JW. In-creased survival of dopaminergic neurons by rasagiline, a mono-amine oxidase B inhibitor. Neuro Report 1998; 9: 703-707.
147. Mytilieou C, Leonardi EK, Radcliffe P., et al. Deprenyl and des-methylselegiline protect mesencephalic neurons from toxicity in-duced by glutathione depletion. J Pharmcol Exp Therap 1998; 284:700-706.
148. Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage in-duced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002; 109: 467-481
149. Naoi M, Maruyama W, Akao Y, Zhang J, Parvez H. Apoptosisinduced by an endogenous neurotoxin, N-methyl(R)salsolinol, indopamine neurons. Toxicology 2000; 153: 123-141.
150. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH,Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326: 105-108.
151. Bar-Am O, Amit T, Youdim MBH. Aminoindan and hydroxyami-noindan, metabolites of rasagiline and ladostigil, respectively, exertneuroprotective properties in vitro. J Neurochem 2007; 103: 500-508.
152. Maruyama W, Yi H, Takahashi T, et al. Neuroprotective functionof R-(-)1-(benzofuran-2-yl)-2-propyl- aminopentane, [R-BPAP],against apoptosis induced by N-methyl(R)salsolinol, an endogenousdopaminergic neurotoxin, in human dopaminergic neuroblastomaSH-SY5Y cells. Life Sci 2004; 75: 107-117.
153. Chiou SH, Ku HH, Tsai TH et al. Moclobemide upregulated Bcl-2expression and induced neural stem cell differentiation into sero-tonergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol 2006; 148: 587-598.
154. Maruyama W, Nitta A, Shamoto-Nagai M, et al. N-Propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotro-phic factor (GDNF) in neuroblastoma SH-SY5Y cells through acti-vation of NF- B transcription factor. Neurochem Int 2004; 44:393-400.
155. Reichardt LF. Neurotrophin-regulated signaling pathways. Phil Trans R Soc B. 2006; 361: 1545-1564.
156. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA,Winslow JW. BDNF mRNA is decreased in the hippocampus ofindividuals with Alzheimer's disease. Neuron 1991; 7: 695-702.
157. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brian Res Rev 2000; 33: 199-227.
158. Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophicfactor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neu-rochem 2002; 82: 1058-1064.
159. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex slic-ing, and multiple promoters. Genomics 2007; 90: 397-406.
160. Peng S, Garzon DJ, Marchese M, et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 2009; 29:9321-9329.
161. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009; 15: 331-337.
162. Feher A, Juhasz A, Rimanoczy A, Kalman J, Janka Z. Association between BDNF Val66Met polymorphism and Alzheimer disease,dementia with Lewy bodies, and Pick disease. Alzheimer Dis As-soc Disord 2009; 23: 224-228.
163. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001; 63: 71-124.
164. Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glialcell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer'sdisease and normal controls. J Alzheimer's Dis 2009; 18: 331-337.
165. Horger BA, Nishimura MC, Armanini MP, et al., Neurtur in expertspotent actions on survival and functions of midbrain dopaminergic neurons. J Neurosci 1998; 18: 4929-4937.
166. Feng L, Wang CY, Jiang H, Oho C, Mizuno K, Dugich-Djordjevic M, Lu B. Differential effects of GDNF and BDNF on cultured ven-tral mesencephalic neurons. Mol Brain Res 1999; 66: 62-70.
167. Sariola H, Saarma M. Novel functions and signaling pathways forGDNF. J Cell Sci 2003; 116: 3853-3862.
168. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 2007; 28: 68-74.
169. Trupp M, Scott R, Whittermore SR, Ibanez CF. Ret-dependent and-independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 1999; 274: 20885-20894.
170. Eriksdotter JM, Nordberg A, Amberla K, et al. Intracerebroven-tricular infusion of nerve growth factor in three patients with Alz-heimer's disease. Dement Geriatr Cogn Disord 1998; 9: 246-257.
171. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999; 46:419-424.
172. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
173. Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson's disease. Nat Neurosci 2004;7: 105-110.
174. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputmental glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 2006; 59: 459-466.
175. Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson'sdisease. Expert Rev Neurother 2008; 8: 1125-1139.
176. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron Disord 2000;1: 201-206.
177. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995; 620: 104-111.
178. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in park-insonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
179. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate model sof Parkinson's disease. Science 2000; 290: 767-773.
180. Ando S, Kobayashi S, Waki H, et al. Animal model of dementiainduced by entorhinal synaptic damage and partial restoration of cognitive deficients by BDNF and carnitine. J Neurosci Res 2002;70: 519-527.
181. Kilic E, Kilic Ü, Hermann DM. TAT-GDNF in neurodegeneration and ischemic stroke, CNS Drug Rev 2005; 11: 369-378.
182. Tatard VM, Singji L, Branton JG, et al. Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor:Survival and differentiation of embryonic dopaminergic neuronsafter grafting in hemi parkinsonian rats. Biomaterials 2007; 29:1978-1988.
183. Johnston LC, Eberling J, Pivirotto P, et al. Clinically relevant effects of convention-enhanced delivery of AAV2-GDNF on the do-paminergic nigrostriatal pathway in aged rhesus monkeys. HumGene Ther 2009; 20: 497-510.
184. Tang YP, Ma YL, Chao CC, Chen KY, Lee EHY. Enhanced glialcell line-derived neurotrophic factor mRNA expression upon deprenyl and melatonin treatment. J Neurosci Res 1998; 53: 593-604
185. Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 2007; 32: 1694-1699.
186. Bar-Am O, Weinreb O, Amit T, Youdim MB. The novel cholines-terase-monoamine oxidase inhibitor and antioxidant, ladostigil,confers neuroprotection in neuroblastoma cells and aged rats. J MolNeurosci 2009; 37: 135-145.
187. Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MBH. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat brain. J Neural Transm 2009; 116: 1456-1472.
188. Gyarfas T, Kuuttila J, Lindholm P, Rantamaki T, Castren E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drugtherapy in vivo. Cell Mol Neurobiol 2010; 30: 361-368.
189. Seniuk NA, Henderson JT, Tatton WG, Roder JC. Increased CTNFgene expression in process-bearing astrocytes following injury is augmented by R deprenyl. J Neurosci Res 1994; 37: 278-286.
190. Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse as-trocytess. Biochem Biophys Res Commun 2000; 279: 751-755.
191. Nakaso K, Nakamura C, Sato H, Imamura K, Takesima T, Naka-shima K. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 2006; 339: 915-922.
192. Webster NJG, Pirrung MC. Small molecule activators of the trk receptors for neuroprotection. BMC Neurosci 2008; 9 (Suppl 2): S1
193. Saarelainen T, Hendolin P, Lucas G, et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 2003; 23: 349-357.
194. Sebastiao AM, Ribeiro JA. Triggering neurotrophic factor action sthrough adenosine A2A receptor activation: implications for neu-roprotection. Br J Pharmacol 2009; 158: 15-22.
195. Ohta K, Kuno S, Mizuta I, Fujinami A, Matsui H, Ohta M. Effects of dopamine agonists, bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci 2003; 73: 617-626.
196. Ohta M, Mizuta I, Ohta K, et al. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes. Biochem Bio-phys Res Commun 2000; 272: 18-22.
197. Hirai C, Takahata K, Shimizu S, et al. Effects of R-BDNF on the expressions of neurotrophins and their receptors in mesen-cephalic slices. Biol Pharm Bull 2005; 28:1524-1526.
198. Holzgrade U, Kapkova P, Alptüzün V, Scheiber J, Kugelmann E.Targeting acetycholinesterase to treat neurodegeneration Exp OpinTher Targets 2007; 11:161-179.
199. Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH. Neuropro-tective effects of donepezil through inhibition of GSK-3 activity inamyloid- -induced neuronal cell death. J Neurochem 2009; 108:1116-1125.
200. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alz-heimer's disease. Preliminary evidence for behavioral change withmonoamine oxidase B inhibition. Arch Gen Psychiatry 1987: 44:427-433.
201. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of se-legiline, alpha tocopherol, or both as treatment for Alzheimer dis-ease. J New Eng J Med 1997; 336: 16-22.
202. Filip V, Kolibas E. Selegiline in the treatment of Alzheimer's dis-ease: a long-term randomized placebo-controlled trial. Czech andSlovak senile dementia of Alzheimer type study group. J PsychiatryNeurosci 1999; 24: 134-143.
203. Freedman M, Rewilak D, Terri T, et al. L-deprenyl in Alzheimer'sdisease: cognitive and behavioral effects. Neurology 1998; 50: 660-668.
204. Takahata K, Minami A, Kusamoto H, Shimizu S, Yoneda F. Ef-fects of selegiline alone or with donepezil on memory impairmentin rats. Eur J Pharmacol 2005; 518: 140-144.
205. Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T. Syner-gistic effects of selegiline and donepezil on cognitive impairmentinduced by amyloid beta (25-35). Behav Brain Res 2008; 190: 224-232.
206. 2+-ATPase activities, antioxidant status, and learningperformance of aged rats. Neuropsychiat Dis Treat 2008; 4: 687-699.
207. Sterling J, Herzig Y, Goren T, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamineas potential treatment for Alzheimer's disease. J Med Chem 2002;45: 5260-5279.
208. Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg JPM, Youdim MBH. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for thetreatment of Alzheimer's disease. J Neural Transm 2000; Suppl 60:157-169.
209. Buccafusco JJ, Terry AV Jr, Goren T, Blaugrun E. Potential cognitive actions of (n-propargyl-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed inold rheusus monkeys in their performance of versions of a delayedmatching task. Neurosience 2003; 119: 669-678.
210. Weinstock M, Gorodetsky E, Poltyerv T, Gross A, Sagi Y, Youdim M. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psy-chiatry 2003; 27: 555-561.
211. Shoham S, Bejar C, Kovalev E, Shorer-Apelbaun D, Weinstock M. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozoto-cin in rats. Neuropharmacol 2007; 52: 836-843.
212. Weintock M, Luques L, Poltyrev T, Bejar C, Shoham S. Ladostigil prevents age-related glial activation and spatial memory deficits inrats. Neurobiol Aging 2009; in press.
213. Maruyama W, Weinstock M, Youdim MBH, Naoi M. Antiapop-totic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 2003; 341: 233-236.
214. Weinreb O, Bar-Am O, Amit T, Driques N, Sagi Y, Youdim MB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 2008; 175: 318-326.
215. Masters C, Beyreuther K. Alzheimer's centennial legacy: prospectsfor rational therapeutic intervention targeting the A amyloid pathway. Brain 2006; 129: 2823-2839.
216. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002; 297: 352-356.
217. Ono K, Hasegawa K, Naiki H, Yamada M. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int 2006; 48: 275-285.
218. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MBH. The involvement of mitogen-activated protein (MAP) kinasein the regulation of amyloid precursor protein processing by novelcholinesterase inhibitors derived from rasagiline. FASEB J 2002;16: 1674-1676.
219. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH.Neuroprotection via pro-survival protein kinase C isoforms associ-ated with Bcl-2 family members. FASEB J 2004; 18: 1471-1473.
220. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2protein family proteins, neurotrophic factors, and APP processingin the neurorescue activity of propargylamine. FASEB J 2005; 19:1899-1901.
221. Yogev-Falach M, Bar-Am O, Amit T, Weinstock M, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regu-lates holo-APP translocation and processing. FASEB J 2006; 20:2177-2179.
222. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MBH. Regulation of protein kinase C by the anti-Parkinson drug, MAO-Binhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004;89: 1119-1125.
223. Yang HO, Ba MW, Ren RJ, et al. Mitogen activated protein kinaseand protein kinase C activation mediate promotion of sAPP secre-tion by deprenyl. Neurochem Int 2007; 50: 74-82
224. Zimmermann M, Gardoni F, Marcello E, et al. Acetylcholine in-hibitors increase ADAM10 activity by promoting its trafficking inneuroblastoma cell lines. J Neurochem 2004; 90: 1489-1499.
225. Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. The impor-tance of propargylamine moiety in the anti-Parkinson drugrasagiline and its derivatives in MAPK-dependent amyloid precur-sor protein processing. FASEB J 2003; 17: 2325-2327
226. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, andevaluation of novel bifunctional iron-chelators as potential agentsfor neuroprotection in Alzheimer's, Parkinson's, and other neu-rodegenerative disease. Bioorg Med Chem 2005; 13: 773-783.
227. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M,Youdim MBH. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase in-hibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 2007; 100: 490-502.
228. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramusculardesferrioxamine in patients with Alzheimer's disease. Lancet 1991;337: 1304-1308.
229. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a cop-per-zinc chelator markedly and rapidly inhibits -amyloid accumu-lation in Alzheimer's disease transgenic mice. Neuron 2001; 30:665-676.
230. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator VK-28,against 6-hydroxydopamine lesion in rats. Neuropharmacol 2004;46: 254-263.
231. Gal S, Zheng H, Fridkin M, Youdim MBH. Novel multifunctionalneuroprotective iron chelator-monoamine oxidase inhibitor drugsfor neurodegenerative diseases. In vivo selective monoamine oxi-dase inhibition and prevention of MPTP-induced striatal dopaminedepletion. J Neurochem 2005; 95: 79-88.
232. Zhu W, Xie W, Pan T, et al., Prevention and restoration of lacta-cystin-induced nigrostriatal dopamine neurons degeneration bynovel brain-permeable iron chelators. FASEB J 2007: 21: 3835-3844.
233. Mattson MP, Chan SL, Duan W. Modification of brain aging andneurodegenerative disorders by genes, diet, and behavior. PhysiolRev 2002; 82: 637-672.
234. Singh M, Arseneult M, Sanderson T, Murthy V, Ramassamy C.Challenges for research on polyphenols from foods in Alzheimer'sdisease: bioavailability, metabolism, and cellular and molecularmechanisms. J Agrc Food Chem 2006; 56: 4855-4873.
235. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, YamadaM. Potent anti-amyloidogenic and fibril-destabilizing effects ofpolyphenols in vitro: implications for the prevention and therapeu-tics of Alzheimer's disease. J Neurochem 2003; 87: 172-181.
236. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril for-mation by polyphenols: Structural similarity and aromatic interac-tions as a common inhibition mechanism. Chem Biol Drug Des 2006; 67: 27-37.
237. Levites Y, Amit T, Mandel S, Youdim MBH. Neuroprotection andneurorescue against A toxicity and PKC-dependent release ofnon-amyloidogenic soluble precursor protein by green tea polyphe-nol epigallocatechin-3-gallate. FASEB J 2003; 17: 952-954.
238. Reznichenko L, Amit T, Zheng H, et al. Reduction of iron-regulated amyloid precursor protein and -amyloid peptide by epigallocatechin-3-gallate in cell cultures: implications for ironchelation in Alzheimer's disease. J Neurochem 2006; 97: 527-536.
239. Rezai-Zadeh K, Shytle D, Sun N, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavageand reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005; 25: 8807-8814.
240. Wang J, Ho L, Zhao W, et al. Grape-derived polyphenols preventA oligomerization and attenuate cognitive deterioration in amouse model of Alzheimer's disease. J Neurochem 2008; 28:6388-6392.
241. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearanceof Alzheimer's disease amyloid- peptides. J Biol Chem 2005;280: 27377-82.
242. Yanez M, Fraiz N, Cano E, Orallo F. Trans-e-vinierin, a poly-phenol present in win, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. EurJ Pharmacol 2006; 542: 54-60.
243. Sloley BD, Urichuk LJ, Morley P, et al. Identification ofkaempferol as monoamine oxidase inhibitor and potential neuro-protectant in extracts of Gingo biloba leaves. J Pharm Pharmacol 2000; 52: 451-459.
244. Chimenti F, Cottiglia F, Bonsignore L, et al. Quercetin as the ac-tive principle of Hypericum hircinum exerts a selective inhibitoryactivity against MAO-A: Extraction, biological analysis, and com-putational study. J Nat Prod 2006; 69: 945-949.
245. Saaby L, Rasmussen HB, Rasmussen, Jäger AK. MAO-A inhibi-tory activity of quercetin from Calluna vulgaris (L.) Hull. J Ethno-pharmacol 2009; 121: 178-181.
246. Han XH, Hong SS, Hwang LS, Lee MK, Hwang BY, Ro JS.Monoamine oxidase inhibitory components from Cayratia japon-ica. Arch Pharmacol Res 2007; 30: 13-17.
247. Hwang JS, Lee SA, Hong SS, et al. Monoamine oxidase inhibitorycomponents from the roots of sophora flavoscens. Arch Pharmacol Res 2005; 28: 190-194.
248. Olsen HT, Stafford GI, Van Staden J, Christensen SB, Jäger AK. Isolation of MAO-inhibitor naringenin from Mentha aquatica (L.).J Enthropharmacol 2008; 117: 500-502.
249. Ahmad M, Saleem S, Ahmad AS, et al. Ginkgo biloba affordsdose-dependent protection against 6-hydroxydopamine-inducedparkinsonism in rats: neurobehavioral, neurochemical and immu-nohistochemical evidences. J Neurochem 2005; 93: 94-104.
250. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. EGb 761 enhancesadult hippocampal neurogenesis and phosphorylation of CREB intransgenic mouse model of Alzheimer's disease. FASEB J 2007; 2:2400-2408.
251. Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA. Protec-tive effect of quercetin in primary neurons against A (1-42): rele-vance to Alzheimer's disease. J Nutr Biochem 2009; 20: 269-275.
252. Pardon MC, Joubert C, Perez-Diaz F, Christen Y, Launay JM,Ohen-Salmon C. In vivo regulation of cerebral monoamine oxidaseactivity in senescent controls and chronically stress-mice by long-term treatment with Ginkgo biloba extract (EGb 761). Mech Age-ing Dev 2000; 113: 157-168.
253. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B bythe polyphenolic compound, curcumin and its metabolite tetrahy-drocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacol 2008; 16: 96-99.
254. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflamma-tion and Alzheimer's disease. J Pharmacol Exp Ther 2008; 326:196-208.
255. Hou WC, Lin RD, Chen CT, Lee MH. Monoamine oxidase B(MAO-B) inhibition by active principles from uncaria rhyncho-phylla. J Ethnopharmacol 2005; 100: 216-220.
256. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y.Anti-depressant natural flavonols modulate BDNF and beta amy-loid in neurons and hippocampus of double TgAD mice. Neuro-pharmacol 2009; 58: 911-920.
257. Raddatz R, Parini A, Lanier SM. Imidazoline/guanidinium bindingdomains on monoamine oxidase. J Biol Chem 1995; 270: 27961-27968.
258. Holt A, Wieland B, Boulton AA. On the binding site of monoamineoxidase inhibitors to some sites distinct from the MAO active site,and effects thereby elicited. Neurotoxicity 2004; 25: 251-266.
259. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection bydeprenyl and other propargylamines; glyceraldehydes-3-phosphatedehydrogenase rather than monoamine oxidase B. J Neural Transm 2003; 110: 509-515.
260. 3H]quipirole binding by monoamine oxidase inhibitors.Life Sci 2002; 71: 2691-2700.
261. Andringa G, Cools AR. The neuroprotective effects of CGP 3466Bin the best in vivo model of Parkinson7s disease, the bilaterallyMPTP-treated rheus monkey. J Neural Transm 2000; Suppl 60:215-225.
262. Parkinson Study Groups. A controlled, randomized, delayed-startstudy of rasagiline in early Parkinson disease, Arch Neurol 2004;61: 561-6.
263. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Eng J Med 2009;361: 1268-1278.
264. Bar-Am O, Amit T, Youdim MBH. Contrasting neuroprotectiveand neurotoxic actions of respective metabolites of anti-Parkinsondrugs rasagiline and selegiline. Neurosci Lett 2004; 355: 169-172.
265. Sun M, Kong L, Wang X, Lu X, Gao Q, Geller A. Comparison ofthe capacity of GDNF, BDNF, or both, to protect nigrostriatal neu-rons in a rat model of Parkinson's disease. Brain Res 2005; 1052:119-129.
266. Mele T, Carman-Krzan M, Juric DM. Regulatory role of mono-amine neurotransmitters in astrocytic NT-3 synthesis. Int J DevNeurosci 2010; 28: 13-19.
267. Lichtlein P, Mohajeri MH. Antibody-based approaches in Alz-heimer's research: safety, pharmacokinetics, and analytical tools. JNeurochem 2008; 104: 859-874.